References
- Citrome L, Volavka J. Violent patients in the emergency setting. Psychiatr Clin North Am 1999; 22(4): 789–801
- Swanson JW. Mental disorder, substance abuse, and community violence: an epidemiological approach. In: Monahan J, Steadman HJ, eds. Violence and mental disorder: developments in risk assessment. Chicago: Univ Chicago Press, 1994: 101–36
- Bick PA, Hannah AL. Intramuscular lorazepam to restrain violent patients. (Letter) Lancet 1986; 1(8474): 206
- Greenblatt DJ, Divoll M, Harmatz JS, et al. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci 1982; 71(2): 248–52
- Dietch JT, Jennings RK. Aggressive dyscontrol in patients treated with benzodiazepines. Clin Psychiatry 1988; 49(5): 184–8
- Citrome L. New antipsychotic medications: what advantages do they offer? Postgrad Med 1997; 101(2): 207–14
- Volavka J, Citrome L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophr Res 1999; 35 Supp1: S23–33
- FDA Psychopharmacological Drugs Advisory Committee. Briefing document for ziprasidone mesylate for intramuscular injection. Feb 15, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3685b2_0l_pfizer.pdf. Accessed Oct 31, 2001
- Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62(1): 12–8
- Reeves KR, Swift RH, Harrigan EP. Ziprasidone intramuscular 10 mg and 20 mg in acute agitation. Presentation at the 151st annual meeting of the American Psychiatric Association, Jun 3, 1998, Toronto. Poster NR494
- Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry 2000; 61(12): 933–41
- Taylor DM, McAskill R. Atypical antipsychotics and weight gain—a systematic review. Acta Psychiatr Scand 2000; 101(6): 416–32
- FDA Psychopharmacological Drugs Advisory Committee. Briefing document for Zyprexa IntraMuscular (olanzapine for injection). Jan 11, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3685bl_01_lilly.pdf. Accessed Oct 31, 2001
- Wright P, Birkett M, David SR, et al. Double- blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158(7): 1149–51
- Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001; 11 (1): 25–32
- Thomas H Jr, Schwartz E, Petrilli R. Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Ann Emerg Med 1992; 21(4): 407–13
- Lischke V, Behne M, Doelken P, et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994; 79(5): 983–6
- Hughes DH. Acute psychopharmacological management of the aggressive psychotic patient. Psychiatr Serv 1999; 50(9): 1135–7
- Siris SG. Three cases of akathisia and “acting out.” J Clin Psychiatry 1985; 46(9): 395–7
- Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159(2): 177–9
- Citrome L, Volavka J. Psychopharmacology of violence. Part II: beyond the acute episode. Psychiatr Ann 1997; 27(10): 696–703